Cannabis Science Inc. Officially Begins Its First Pre-IND FDA Application Process For Post Traumatic Stress Disorder (PTSD)
3/2/2010 9:44:10 AM
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science Inc. (NASD OTCBB: CBIS), a pharmaceutical cannabis company in the US, is pleased to announce that it now has the results of its survey of more than 1,300 individuals with PTSD, including a large cohort of veterans. The survey was conducted by Cannabis Science Advisory Board member Dr. Mitch Earleywine PhD. of the State University of New York (Albany).